Guselkumab is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
It is indicated for the treatment of adults with active psoriatic arthritis.
Serious hypersensitivity reactions, including anaphylaxis, have been reported.
It may increase the risk of infection, and should not be initiated in patients with a clinically important active infection.
Patients should be evaluated for tuberculosis prior to the initiation of treatment.
Prior to the initiation of treatment patient should be evaluated for current immunization guidelines.
Adverse reactions include: upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.
It is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4.
It may be administered alone or in combination with a cDMARD